European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Genome editing using CRISPR/Cas9 complexes that respond to two different acidity levels

Updated

Abstract

The most potent LAF-dGtp analogues achieved an EC50 of 0.51 nM in a Duchenne muscular dystrophy reporter cell line.

  • Dual pH-responsive amphiphilic xenopeptides were evaluated for delivering CRISPR/Cas9 RNP.
  • Enhanced cellular uptake and effective endosomal disruption were observed in HeLa cells.
  • Cas9/sgRNA RNP complexes demonstrated potent genome editing capabilities across four different cell lines.
  • Comparative analysis showed similar splice site editing and exon skipping between Cas9/sgRNA RNP complexes and Cas9 mRNA/sgRNA polyplexes.
  • A carrier complexing Cas9/sgRNA RNP and donor DNA facilitated up to 43% homology-directed repair in HeLa cells.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest There are no conflicts to declare.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free